A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age70+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.
Eligibility criteria
Qualifiers
Patients must have histologically confirmed adenocarcinoma of the breast confirmed at MSK. The patient must have had diagnostic biopsy or completion of primary surgical management, within 3 months of enrollment. Results of HER-2/neu, estrogen receptor, and progesterone receptor are required for study entry.
Patients must be ≥ 70 years of age.
Patients must have ECOG performance status >2 (Karnofsky score of ≥ 60%).
Patients may have received hormonal therapy for the purpose of chemoprevention.
Disqualifiers
Stage IV breast cancer
CARG score- high Frail 4 or more as assessed by CAIT
Her 2 Neu positive 3+/amplified breast cancer
No prior chemotherapy within 1 year of study enrollment
Trial design
Treatments tested in this trial
- CMF Regimen
- Paclitaxel
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov